Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jan 13,2021
Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area
Recently, Shanghai Medicilon was awarded the title of "Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of "2020
More
Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area
Jan 04,2021
Medicilon's Top 10 Greatest Achievements in 2020
Medicilon embodies its motto of being "Innovation-driven, quality-focused" and keeps on maintaining and improving its technology and quality of services.
More
Medicilon's Top 10 Greatest Achievements in 2020
Jan 01,2021
Medicilon's pharmacology models for inflammatory-immune diseases
Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and
More
Medicilon's pharmacology models for inflammatory-immune diseases
Dec 25,2020
Medicilon is Listed as the 2020 TOP10 Innovation CRO in China
Dec.20, 2020, Hebei—The 13th China Pharmaceutical Strategy Conference 2020 was held successfully. The conference presented the list of "the 2020 TOP10 Innovation CRO in China”.
More
Medicilon is Listed as the 2020 TOP10 Innovation CRO in China
Dec 25,2020
Medicilon's CDMO Service Platform
Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative medicine R&D, production, packaging, inspections and stability tests.
More
Medicilon's CDMO Service Platform
Dec 22,2020
Warmest Holiday Season Greeting From Medicilon 2021
Warmest Holiday Season Greeting From Medicilon. Medicilon wishes you peace,joy and prosperity throughout the coming year.
More
Warmest Holiday Season Greeting From Medicilon 2021
Dec 04,2020
CGeneTech and Medicilon Held the Conference Titled "PROTAC Project Contract Signing & Kick-off Meeting”
Shanghai, China, Dec. 2nd, 2020 — CGeneTech (Suzhou, China) Co., Ltd and Medicilon Inc. successfully held the conference titled "PROTAC project contract signing & kick-off
More
CGeneTech and Medicilon Held the Conference Titled "PROTAC Project Contract Signing & Kick-off Meeting”
Dec 01,2020
Medicilon's Immuno-oncology Models Evaluation Platform
In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor
More
Medicilon's Immuno-oncology Models Evaluation Platform
Nov 24,2020
Medicilon Wish You a Safe, Healthy and Warm Thanksgiving
#medicilon #thanksgiving #drugdiscovery
More
Medicilon Wish You a Safe, Healthy and Warm Thanksgiving
Nov 16,2020
Medicilon will participate ACT 2020 Annual Meeting
#Medicilon will exhibit the ACT 2020 Annual Meeting Nov 12-19.  Please visit our virtual booth for our #toxicology services.  We look forward to see you.
More
Medicilon will participate ACT 2020 Annual Meeting
Nov 11,2020
Medicilon will participate SAPA-CT Annual Conference
Medicilon will exhibit the SAPA-CT Annual Conference on Nov 14, 2020.  Our CEO, Dr. Chunlin Chen, is invited to give a presentation on the topic
More
Medicilon will participate SAPA-CT Annual Conference
Oct 31,2020
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.
More
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"